Cell biology of protein misfolding: The examples of Alzheimer's and Parkinson's diseases

Nature Cell Biology

Volumn 6, Issue 11, 2004, Pages 1054-1061

  Selkoe, Dennis J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID A PROTEIN; AMYLOID PRECURSOR PROTEIN; ASPARTIC PROTEINASE; BETA SECRETASE; NOTCH RECEPTOR; PRESENILIN; TAU PROTEIN; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CYTOLOGY; CYTOTOXICITY; DEGENERATIVE DISEASE; HUMAN; LIPID BILAYER; MITOSIS; NONHUMAN; OLIGOMERIZATION; PARKINSON DISEASE; PATHOLOGY; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN PROCESSING; REVIEW; SOLUBILITY;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; HUMANS; MOLECULAR SEQUENCE DATA; PARKINSON DISEASE; PHENOTYPE; PROTEIN FOLDING;

EID: 7944233158     PISSN: 14657392     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncb1104-1054     Document Type: Review

References (104)

1. Selkoe, D. J., Ihara, Y. & Salazar, F. Alzheimer's disease: insolubility of partially purified paired helical filaments in sodium dodecyl sulfate and urea. Science 215, 1243-1245 (1982).
2. Nukina, N. & Ihara, Y. Proteolytic fragments of Alzheimer's paired helical filaments. J Biochem (Tokyo) 98, 1715-1718 (1985).
3. Grundke-Iqbal, I. et al. Abnormal phosphorylation of the microtubule-associated protein t (tau) in Alzheimer cytoskeletal pathology. Proc. Natl Acad. Sci. USA 83, 4913-4917 (1986).
4. Kosik, K. S., Joachim, C. L. & Selkoe, D. J. Microtubule-associated protein, tau, is a major antigenic component of paired helical filaments in Alzheimer's disease. Proc. Natl Acad. Sci. USA 83, 4044-4048 (1986).
5. Wischik, C. M. et al. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer's disease. Proc. Natl Acad. Sci. USA 85, 4506-4510 (1988).
6. Lee, V. M.-Y., Balin, B. J., Otvos, L. & Trojanowski, J. Q. A68: A major subunit of paired helical filaments and derivatized forms of normal tau. Science 251, 675-678 (1991).
7. Lee, V. M., Goedert, M. & Trojanowski, J. Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 1121-1159 (2001).
8. Glenner, G. G. & Wong, C. W. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885-890 (1984).
9. Masters, C. L. et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl Acad. Sci. USA 82, 4245-4249 (1985).
10. Selkoe, D. J. Cell biology of the amyloid β-protein precursor and the mechanism of Alzheimer's disease. Annu. Rev. Cell Biol. 10, 373-403 (1994).
11. Kang, J. et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325, 733-736 (1987).
12. Haass, C. et al. Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 359, 322-325 (1992).
13. Seubert, P. et al. Isolation and quantitation of soluble Alzheimer's β-peptide from biological fluids. Nature 359, 325-327 (1992).
14. Shoji, M. et al. Production of the Alzheimer amyloid β protein by normal proteolytic processing. Science 258, 126-129 (1992).
15. Vassar, R. & Citron, M. Aβ-generating enzymes: recent advances in β-and γ-secretase research. Neuron 27, 419-422 (2000).
16. Kimberly, W. T. et al. γ-Secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1 and Pen-2. Proc. Natl Acad. Sci. USA 100, 6382-6387 (2003).
17. Takasugi, N. et al. The role of presenilin cofactors in the γ-secretase complex. Nature 422, 438-441 (2003).
18. Edbauer, D. et al. Reconstitution of γ-secretase activity. Nature Cell Biol. 5, 486-488 (2003).
19. Buxbaum, J. D. et al. Evidence that tumor necrosis factor α converting enzyme is involved in regulated α -secretase cleavage of the Alzheimer amyloid protein precursor. J. Biol. Chem. 273, 27765-27767 (1998).
20. Parkin, E. T. et al. Structure-activity relationship of hydroxamate-based inhibitors on the secretases that cleave the amyloid precursor protein, angiotensin converting enzyme, CD23, and pro-tumor necrosis factor-α. Biochemistry 41, 4972-4981 (2002).
21. Haass, C., Hung, A. Y., Schlossmacher, M. G., Teplow, D. B. & Selkoe, D. J. β-amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms. J. Biol. Chem. 268, 3021-3024 (1993).
22. Cao, X. & Sudhof, T. C. A transcriptionally active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 293, 115-120 (2001).
23. Kimberly, W. T., Zheng, J. B., Guenette, S. Y. & Selkoe, D. J. The intracellular domain of the β-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a Notch-like manner. J. Biol. Chem. 276, 40288-40292 (2001).
24. Cao, X. & Sudhof, T. C. Dissection of amyloid-β precursor protein-dependent transcriptional transactivation. J. Biol. Chem. 279, 24601-24611 (2004).
25. Zheng, H. et al. β-amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell 81, 525-531 (1995).
26. Perez, R. G., Zheng, H., Van der Ploeg, L. H. & Koo, E. H. The β-amyloid precursor protein of Alzheimer's disease enhances neuron viability and modulates neuronal polarity. J. Neurosci. 17, 9407-9414 (1997).
27. Sherrington, R. et al. Cloning of a novel gene bearing missense mutations in early onset familial Alzheimer disease. Nature 375, 754-760 (1995).
28. Levy-Lahad, E. et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269, 973-977 (1995).
29. Levitan, D. & Greenwald, I. Facilitation of lin-12- ediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimer's disease gene. Nature 377, 351-354 (1995).
30. De Strooper, B. et al. A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain. Nature 398, 518-522 (1999).
31. Struhl, G. & Greenwald, I. Presenilin is required for activity and nuclear access of Notch in Drosophila. Nature 398, 522-525 (1999).
32. Ye, Y., Lukinova, N. & Fortini, M. E. Neurogenic phenotypes and altered Notch processing in Drosophila Presenilin mutants. Nature 398, 525-529 (1999).
33. De Strooper, B. et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391, 387-390 (1998).
34. Wolfe, M. S. et al. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ -secretase activity. Nature 398, 513-517 (1999).
35. Li, Y.-M. et al. Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 405, 689-694 (2000).
36. Esler, W. P. et al. Transition-state analogue inhibitors of γ-secretase bind directly to presenilin-1. Nature Cell Biol. 2, 428-434 (2000).
37. Struhl, G. & Adachi, A. Requirements for presenilin-dependent cleavage of notch and other transmembrane proteins. Mol. Cell 6, 625-636 (2000).
38. Goate, A. et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704-706 (1991).
39. Strittmatter, W. J. et al. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl Acad. Sci. USA 90, 1977-1981 (1993).
40. Citron, M. et al. Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production. Nature 360, 672-674 (1992).
41. Suzuki, N. et al. An increased percentage of long amyloid β protein secreted by familial amyloid β protein precursor (βAPP717) mutants. Science 264, 1336-1340 (1994).
42. Games, D. et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373, 523-527 (1995).
43. Hsiao, K. et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274, 99-102 (1996).
44. Scheuner, D. et al. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Med. 2, 864-870 (1996).
45. Levy, E. et al. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch-type. Science 248, 1124-1126 (1990).
46. Clements, A., Walsh, D. M., Williams, C. H. & Allsop, D. Effects of the mutations Glu22 to Gln and Ala21 to Gly on the aggregation of a synthetic fragment of the Alzheimer's amyloid b/A4 peptide. Neurosci. Lett. 161, 17-20 (1993).
47. De Jonghe, C. et al. Flemish and Dutch mutations in amyloid β precursor protein have different effects on amyloid β secretion. Neurobiol. Dis. 5, 281-286 (1998).
48. Nilsberth, C. et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation. Nature Neurosci. 4, 887-893 (2001).
49. Lemere, C. A. et al. Sequence of deposition of heterogeneous amyloid β-peptides and Apo E in Down syndrome: Implications for initial events in amyloid plaque formation. Neurobiol. Dis. 3, 16-32 (1996).
50. Saunders, A. M. et al. Association of apolipoprotein E allele E 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43, 1467-1472 (1993).
51. Schmechel, D. E. et al. Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl Acad. Sci. USA 90, 9649-9653 (1993).
52. Holtzman, D. M. et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 97, 2892-2897 (2000).
53. Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356 (2002).
54. Urbanc, B. et al. Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease. Proc. Natl Acad. Sci. USA 99, 13990-13995 (2002).
55. Koo, E. H. et al. Precursor of amyloid protein in Alzheimer's disease undergoes fast anterograde axonal transport. Proc. Natl Acad. Sci. USA 87, 1561-1565 (1990).
56. Kamal, A., Almenar-Queralt, A., LeBlanc, J. F., Roberts, E. A. & Goldstein, L. S. Kinesin-mediated axonal transport of a membrane compartment containing β-secretase and presenilin-1 requires APP. Nature 414, 643-648 (2001).
57. Naslund, J. et al. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA 283, 1571-1577 (2000).
58. McLean, C. A. et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46, 860-866 (1999).
59. Lue, L. F. et al. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155, 853-862 (1999).
60. Hsia, A. Y. et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. USA 96, 3228-3233 (1999).
61. Mucke, L. et al. High-level neuronal expression of Aβ1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 4050-4058 (2000).
62. Larson, J., Lynch, G., Games, D. & Seubert, P. Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice. Brain Res. 840, 23-35 (1999).
63. Moechars, D. et al. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem. 274, 6483-6492 (1999).
64. Walsh, D. et al. Naturally secreted oligomers of the Alzheimer amyloid β-protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539 (2002).
65. Cleary, J. P. et al. Naturally assembled Aβ oligomers produce cognitive deficits. Soc. Neurosci. Abstr. 772.11 (2003).
66. Dodart, J. C. et al. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nature Neurosci. 5, 452-457 (2002).
67. Barghorn, S. & Mandelkow, E. Toward a unified scheme for the aggregation of tau into Alzheimer paired helical filaments. Biochemistry 41, 14885-14896 (2002).
68. Hutton, M. et al. Association of missense and 5′-splice-site mutations in tau with the inherited FTDP-17. Nature 393, 702-705 (1998).
69. Poorkaj, P. et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 43, 815-825 (1998).
70. Spillantini, M. G. et al. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl Acad. Sci. USA 95, 7737-7741 (1998).
71. Lewis, J. et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 1487-1491 (2001).
72. Gotz, J., Chen, F., van Dorpe, J. & Nitsch, R. M. Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by Aβ 42 fibrils. Science 293, 1491-1495 (2001).
73. Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H. & LaFerla, F. M. Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43, 1-20 (2004).
74. Patrick, G. N. et al. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402, 615-622 (1999).
75. McGeer, P. L. & McGeer, E. G. Inflammation, autotoxicity and Alzheimer disease. Neurobiol. Aging 22, 799-809 (2001).
76. Weggen, S. et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 414, 212-216 (2001).
77. Koo, E. H. & Squazzo, S. Evidence that production and release of amyloid β-protein involves the endocytic pathway. J. Biol. Chem. 269, 17386-17389 (1994).
78. Hartmann, T. et al. Distinct sites of intracellular production for Alzheimer's disease Aβ-40/42 amyloid peptides. Nature Med. 3, 1016-1020 (1997).
79. Cook, D. G. et al. Alzheimer's Aβ (1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nature Med. 3, 1021-1023 (1997).
80. Gouras, G. K. et al. Intraneuronal Aβ42 accumulation in human brain. Am. J. Pathol. 156, 15-20 (2000).
81. Annaert, W. G. et al. Presenilin 1 controls γ-secretase processing of amyloid precursor protein in pre-Golgi compartments of hippocampal neurons. J. Cell Biol. 147, 277-294 (1999).
82. Ray, W. J. et al. Cell surface presenilin-1 participates in the γ-secretase-like proteolysis of notch. J Biol Chem 274, 36801-36807 (1999).
83. Chyung, J. H. & Selkoe, D. J. Cell surface events in APP processing to generate Aβ. Soc. Neurosci. Abstr. 295.9 (2003).
84. Dawson, T. M. & Dawson, V. L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 302, 819-822 (2003).
85. Polymeropoulos, M. H. et al. Mutation in the α-synuclein gene identified in families with Parkinsons disease. Science 276, 2045-2047 (1997).
86. Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M. & Goedert, M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl Acad. Sci. USA 95, 6469-6473 (1998).
87. Baba, M. et al. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879-884 (1998).
88. Sherer, T. B., Kim, J. H., Betarbet, R. & Greenamyre, J. T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and α-synuclein aggregation. Exp. Neurol. 179, 9-16 (2003).
89. Ischiropoulos, H. & Beckman, J. S. Oxidative stress and nitration in neurodegeneration: cause, effect, or association? J. Clin. Invest. 111, 163-169 (2003).
90. Dauer, W. et al. Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl Acad. Sci. USA 99, 14524-14529 (2002).
91. Lansbury, P. T. Jr. & Brice, A. Genetics of Parkinson's disease and biochemical studies of implicated gene products. Curr. Opin. Genet. Dev. 12, 299-306 (2002).
92. Singleton, A. B. et al. α-Synuclein locus triplication causes Parkinson's disease. Science 302, 841 (2003).
93. Kitada, T. et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608 (1998).
94. Shimura, H. et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nature Genet. 25, 302-305 (2000).
95. Zhang, Y. et al. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl Acad. Sci. USA 97, 13354-13359 (2000).
96. Goldberg, M. S. et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem. 278, 43628-43635 (2003).
97. Palacino, J. J. et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem. 279, 18614-18622 (2004).
98. Greenamyre, J. T. & Hastings, T. G. Biomedicine, Parkinson's - divergent causes, convergent mechanisms. Science 304, 1120-1122 (2004).
99. Vila, M. & Przedborski, S. Targeting programmed cell death in neurodegenerative diseases. Nature Rev. Neurosci. 4, 365-375 (2003).
100. Leroy, E. et al. The ubiquitin pathway in Parkinson's disease. Nature 395, 451-452 (1998).
101. Bonifati, V. et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299, 256-259 (2003).
102. Valente, E. M. et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304, 1158-1160 (2004).
103. Liu, Y., Fallon, L., Lashuel, H. A., Liu, Z. & Lansbury, P. T. Jr. The UCH-L1 gene encodes two opposing enzymatic activities that affect α-synuclein degradation and Parkinson's disease susceptibility. Cell 111, 209-218 (2002).
104. Quigley, P. M., Korotkov, K., Baneyx, F. & Hol, W. G. The 1.6-A crystal structure of the class of chaperones represented by Escherichia coli Hsp31 reveals a putative catalytic triad. Proc. Natl Acad. Sci. USA 100, 3137-3142 (2003).